Skip to main content

Table 5 Percentage change in IOP (mmHg) from baseline to week 4 (ANCOVA, PP population)

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

  Latanoprost concentration (μg/mL)
  50 75 100 125
N 69 66 71 68
Worse eye
8 a.m. IOP
 LS mean change (mmHg)* −37.6 −35.5 −37.3 −33.5
 Difference in LS mean change ± SEM   2.2 ± 1.7 0.3 ± 1.7 4.1 ± 1.7
 (90% CI)   (−0.06, 5.0) (−2.4, 3.1) (1.3, 6.8)
 p-value   0.899 0.581 0.992
Study eye
8 a.m. IOP
 LS mean change (mmHg)* −37.2 −35.0 −36.4 −33.3
 Difference in LS mean change ± SEM   2.2 ± 1.7 0.8 ± 1.6 3.8 ± 1.6
 (90% CI)   (−0.6, 4.9) (−1.9, 3.4) (1.1, 6.5)
 p-value   0.906 0.682 0.990
  1. ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
  2. *Adjusting for baseline IOP (covariate) with dose group and center as factors.
  3. Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
  4. One-sided p-value.